This phase I/II trial evaluates the safety and activity of an anti-cancer drug in children or young people with relapsed or refractory leukaemia, neuroblastoma, sarcoma or high grade glioma.
This trial is treating patients with leukaemia, neuroblastoma, sarcoma or high grade glioma (brain cancer).
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase I/II Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100) in Relapsed/Refractory Cancers of Children and Young Adults
Other Non-Commercial Sponsor
University of Birmingham
Eligible patients will be assigned to experimental groups dependant on their condition; Leukaemia, Neuroblastoma, Sarcomas and High Grade Glioma. Each group will receive a weekly IV infusion of PEG- BCT-100.
Recruiting Hospitals Read More